Published in Chem Biol Drug Des on March 06, 2016
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 12.52
Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol (2000) 5.75
Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell (1995) 5.68
Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem (2006) 4.74
The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature (2005) 4.63
Sending signals dynamically. Science (2009) 3.64
Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol (2005) 3.51
Monastrol inhibition of the mitotic kinesin Eg5. J Biol Chem (2005) 3.49
Chemotherapy-induced peripheral neuropathy. J Neurol (2002) 3.09
The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. J Cell Biol (1999) 2.82
Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J Biol Chem (2001) 2.18
Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell (2005) 2.16
S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem (2006) 2.09
Allostery: an illustrated definition for the 'second secret of life'. Trends Biochem Sci (2008) 1.99
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther (2004) 1.98
An atomic-level mechanism for activation of the kinesin molecular motors. Proc Natl Acad Sci U S A (2010) 1.93
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A (2010) 1.72
Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev (2009) 1.60
Dynamic allostery: linkers are not merely flexible. Structure (2011) 1.58
Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol (2004) 1.58
Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry (2003) 1.51
Full correlation analysis of conformational protein dynamics. Proteins (2008) 1.47
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol (2007) 1.39
Docking and rolling, a model of how the mitotic motor Eg5 works. J Biol Chem (2005) 1.30
Signaling pathways of PDZ2 domain: a molecular dynamics interaction correlation analysis. Proteins (2009) 1.29
Protein functional landscapes, dynamics, allostery: a tortuous path towards a universal theoretical framework. Q Rev Biophys (2010) 1.29
Mechanism of taxane neurotoxicity. Breast Cancer (2004) 1.26
Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem Biol Drug Des (2010) 1.24
Novel allosteric sites on Ras for lead generation. PLoS One (2011) 1.20
Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem Biol (2006) 1.19
Whence cometh the allosterome? Proc Natl Acad Sci U S A (2006) 1.17
Molecular dynamics simulation of the Escherichia coli NikR protein: equilibrium conformational fluctuations reveal interdomain allosteric communication pathways. J Mol Biol (2008) 1.10
Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci (2004) 1.07
The structural basis of force generation by the mitotic motor kinesin-5. J Biol Chem (2012) 1.06
Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol (2011) 1.06
Crystal structure of the motor domain of the human kinetochore protein CENP-E. J Mol Biol (2004) 1.04
Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem (2008) 1.04
A pathway of structural changes produced by monastrol binding to Eg5. J Biol Chem (2006) 1.04
Loop L5 acts as a conformational latch in the mitotic kinesin Eg5. J Biol Chem (2010) 1.02
Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys (2007) 0.99
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorg Med Chem Lett (2006) 0.97
Conformational transition pathway in the allosteric process of human glucokinase. Proc Natl Acad Sci U S A (2006) 0.97
Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem (2007) 0.96
Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J Mol Biol (2006) 0.96
Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1. ACS Chem Biol (2013) 0.95
Complete relaxation and conformational exchange matrix (CORCEMA) analysis of intermolecular saturation transfer effects in reversibly forming ligand-receptor complexes. J Magn Reson (2002) 0.95
Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem (2013) 0.94
Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol (2001) 0.93
NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site. Biochemistry (2009) 0.93
Allosteric regulation of protease activity by small molecules. Mol Biosyst (2010) 0.92
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl (2011) 0.91
Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr Top Med Chem (2008) 0.91
Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. J Biol Chem (2007) 0.88
KIFC1 is a novel potential therapeutic target for breast cancer. Cancer Biol Ther (2015) 0.85
CORCEMA refinement of the bound ligand conformation within the protein binding pocket in reversibly forming weak complexes using STD-NMR intensities. J Magn Reson (2004) 0.85
Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors. Bioorg Med Chem Lett (2007) 0.85
Kif3a is necessary for initiation and maintenance of medulloblastoma. Carcinogenesis (2013) 0.85
Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors. Bioorg Med Chem Lett (2009) 0.85
Structural insights into a unique inhibitor binding pocket in kinesin spindle protein. J Am Chem Soc (2013) 0.85
The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5. Bioorg Med Chem Lett (2009) 0.83
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain. Biochemistry (2010) 0.83
Exploring the intermediate states of ADP-ATP exchange: a simulation study on Eg5. J Phys Chem B (2010) 0.83
"Fluctuograms" reveal the intermittent intra-protein communication in subtilisin Carlsberg and correlate mechanical coupling with co-evolution. PLoS Comput Biol (2011) 0.81
Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator. J Am Chem Soc (2008) 0.81